Our proprietary microbiome research begins with extensive preclinical research on target strains. The best candidates are tested in randomized, double-blind, placebo-controlled human studies to provide scientific evidence of effectiveness.
Postbiotic innovation at ADM
ADM is driving postbiotic innovation on a global scale. Backed by our advanced proprietary microbiome research capabilities, we deliver science-led postbiotic solutions specifically targeted to meet evolving consumer needs.
From preclinical discovery to commercial scale
ADM’s cutting-edge postbiotic innovations are grounded in preclinical discovery and industry-leading microbiome research—and are shaped by the need for better solutions for consumers, manufacturers, researchers, and professionals alike.
Every ingredient we formulate is subjected to rigorous in vitro, preclinical, and human studies, and today our clinical evidence base is among the deepest in the industry. You also get more than a science-backed ingredient. With ADM, you’ll get a partner from concept to full-scale commercial production.
ADM’s industry experts and global capabilities enable us to provide end-to-end support, from formulation support to application development to finished-format manufacturing at our state-of-the-art production facility. Together, we’ll help you to get to market faster with premium solutions that connect with consumers.
We turn postbiotics into real products people want to use. Our proprietary heat-treated whole-cell technology locks in efficacy while increasing stability, opening up a broad range of formulation possibilities, applications, and delivery formats.
ADM’s postbiotics are heat-stable, so they can withstand harsh processing conditions while eliminating the need for dedicated cold manufacturing or cold chain. Finished products are premium-quality and remain effective throughout their shelf-life.
From strain identification to postbiotic innovation
Postbiotic innovation is unlocking new possibilities. For example, BPL1® Postbiotic ( CECT 8145) is developed from our proprietary probiotic strain. Emerging and evidence suggest it may help support visceral fat reduction in combination with diet and exercise, while offering high formulation flexibility.
Our clinically backed postbiotics
ADM’s industry-leading microbiome research has led to the innovation of three clinically backed, targeted postbiotic products.
BPL1® for metabolic health
ADM’s innovative BPL1® Postbiotic is clinically studied to support metabolic health in combination with diet and exercise¹.
Esflorin1® for digestive health
Clinical evidence shows Esflorin1® Postbiotic may help reduce bloating, and support overall gut health³.
L. gasseri CP2305 for mental wellbeing
With 10 human clinical trials, this is shown to help support stress, mood, sleep, women’s health, and men’s exercise recovery.
We’re shaping the next generation of microbiome solutions. Discover how we can help you, from postbiotic research to new formulations to product development.
Hi! We're Performing Maintenance.
ERROR CODE: 503
Here are some helpful links
Hello
This content is intended for business-to-business (B2B) informational purposes only and not directed to consumers. The information provided summarizes scientific research and should not be interpreted as evidence that any ingredient, product, claim, or statement has been approved, authorized, validated, or accepted by any regulatory authority in any jurisdiction. References to scientific studies do not establish that any claim is permitted for use in a particular jurisdiction or product category. The ingredients described in this content are not intended to diagnose, treat, cure, or prevent any disease. Ingredients, permitted uses, and claims must be reviewed under applicable local laws and regulations before use in any specific product, category, or market by companies for their finished products.
Sources
BPL1® and Esflorin1® are trademarks registered for Biopolis S.L. in the EU and other countries.
¹Pedret et al. (2019), International Journal of Obesity, 43:1863–1868
²Salminen et al. (2021), Nature Reviews Gastroenterology & Hepatology, 18:649–667
³Esflorin1® Postbiotic clinical studies:
Srivastava et al. (2024), Gut Microbes, 16:2338322
Naghibi et al. (2024), Nutrients, 16:3952
Cardoso et al. (2026), Allergy, 1–13
⁴L. gasseri CP2305 Postbiotic clinical studies:
Sugawara et al. (2016), Microbial Ecology in Health and Disease, 27:30259
Nishida et al. (2017), Journal of Applied Microbiology, 123:1561–1570
Nishida et al. (2017), Journal of Functional Foods, 36:112–121
Nishida et al. (2019), Nutrients, 11:1859
Chu et al. (2023), Clinical Nutrition, 42:1314–1321
Nishida et al. (2021), Journal of Functional Foods, 80:104426
Sawada et al. (2022), Nutrients, 14:1695
Sawada et al. (2019), Journal of Functional Foods, 57:465–476
Tanihiro et al. (2026), Frontiers in Nutrition, 13:1796729
Fuchida et al. (2026), Toxicology Reports, 16:102222